Preparation of high purity substituted quinoxaline

Details for Australian Patent Application No. 2006217616 (hide)

Owner Pfizer Products Inc.

Inventors Watson, Timothy James Norman; Withbroe, Gregory John; Mustakis, Lasson Georgios; Sinay, Terry Gene Jr.; Hawkins, Joel Michael; Busch, Frank Robert

Agent Spruson & Ferguson

Pub. Number AU-A-2006217616

PCT Pub. Number WO2006/090236

Priority 60/656,296 24.02.05 US

Filing date 21 February 2006

Wipo publication date 31 August 2006

International Classifications

C07D 471/08 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

Event Publications

6 September 2007 PCT application entered the National Phase

  PCT publication WO2006/090236 Priority application(s): WO2006/090236

4 November 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006217630-Substituted 1,1,1-trifluoro-3-[(benzyl)-(pyrimidin-2-yl )-amino]-prop an-2-ol compounds

2006217615-5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases